?immunosuppressive

immunosuppressive發(fā)音

英：[?'mju:n??s?'pres?v]　　美：[??mj?no?s?'pres?v]

英：　　美：

immunosuppressive中文意思翻譯

adj. 抑制免疫反應的

immunosuppressive詞形變化

形容詞: immunosuppressive | 名詞: immunosuppressant |

immunosuppressive常見(jiàn)例句

1 、Maybe, but the immunosuppressants that he's gonna be on posttransplant should ensure that his body doesn't reject the organ.─── 也許吧 但是他在移植后注射的 免疫抑制劑 會(huì )確保他的身體不會(huì )排斥新的器官

2 、Marek's disease is an important immunosuppressive disease, which seriously affects the healthy development of the poultry industry.───摘要馬立克氏病是一種重要的免疫抑制病，嚴重影響養雞業(yè)的健康發(fā)展。

3 、Antitumor Activity of Monoclonal Antibody MI-2 Against Immunosuppressive Acidic Protein in Vitro───免疫抑制酸性蛋白單克隆抗體MI-2體外抗腫瘤作用的觀(guān)察

4 、We herein made a review on the immunosuppressive effect of mesenchymal stem cell and its mechanism.───本文簡(jiǎn)要綜述間充質(zhì)干細胞的免疫抑制作用和機理。

5 、The Relationship between Antisperm Plasma Immunosuppressive Factor IgG and IgA in Seminal Plasma of Infertile Man───不育男子精漿中抗精漿免疫抑制因子IgG和IgA的相關(guān)性分析及臨床意義

6 、But I can tell you, via pharmacy records, that immunosuppressants were prescribed.─── 但是我可以告訴你 藥房記錄顯示 近期開(kāi)過(guò)免疫抑制劑

7 、The BABL/C mice were either treated with Cyclosporin A (CsA) cr Cyclophosphamide (CY) as immunosuppressive mod- els.───將 BABL/C 小鼠用環(huán)胞霉素 A(CsA)和環(huán)**酰胺(Cy)造成免疫抑制小鼠。

8 、If the use of western medicine, can be used immunosuppressive drugs such as azathioprine, not premature use of glucocorticoids.───如果使用西藥，可用硫唑嘌呤等免疫抑制藥，不要過(guò)早的使用皮質(zhì)激素。

9 、Peter rossing :Firstly some non-diabetic kidney diseases need specific treatment such as immunosuppressive therapy.───其二，二者預后非常不同，與糖尿病腎病相比，某些非糖尿病腎病的預后很好。

10 、immunosuppressive acidic protein───IAP

11 、Effect of immunosuppressive substance from serum of traumatized rabbit on IL - 2 and IL - 2R───創(chuàng )傷家兔血清免疫抑制物對小鼠淋巴細胞IL-2及IL-2R的影響

12 、Immunosuppressive antibiotic───免疫抑制劑

13 、Pharmacological activity-guided evaluation of the immunosuppressive fractions and components from Cornus officinals───山茱萸體液免疫抑制活性成分的藥理學(xué)導向評價(jià)分離

14 、He's got everything in there steroids, immunosuppressants, antifungals, antibiotics, pain medication.─── 他什么都有 類(lèi)固醇 免疫抑制劑 抗真菌藥 抗生素 止痛藥

15 、Yoshiba M, et al. (1992) Activation of hepatitis C virus following immunosuppressive treatment.───李峰,等。**酸川芎口秦與大鼠肝微粒體相互作用的研究。

16 、immunosuppressive measles encephalopathy───免疫抑制性麻疹性腦病

17 、Human immunosuppressive acidic protein，IAP Eli...───人免疫抑制酸性蛋白（IAP）試劑盒；

18 、Saving a 16yearold kid from a lifetime of immunosuppressant drugs and a very nasty scar.─── 把一個(gè)16歲的孩子從終生的免疫抑制劑 和無(wú)法修復的手術(shù)傷疤中解救出來(lái)

19 、Clinical Application of Immunosuppressive Turbidimetry in Determining Glycosylation hemoglobin───免疫抑制比濁法測定糖化血紅蛋白的臨床應用

20 、antibiotics are immunosuppressive───抗菌素對免疫有抑制作用。

21 、Because ASATI uses the body's own natural responses, this intervention has the potential to be far safer than immunosuppressive drugs that are now being studied.───因為asati利用人體自身的天然反應，這種干預有可能遠遠超過(guò)安全的免疫抑制藥物，目前正在研究。

22 、Joseph Murray, MD, receives the Nobel Prize in 1990 for this work and the subsequent development of immunosuppressive drugs (Peter Bent Brigham Hospital).───醫學(xué)博士約瑟芬.墨里在1990年由于這項工作獲得了諾貝爾獎金。隨后又發(fā)展出了免抑制疫力的藥物。（彼得.本特.布賴(lài)海姆醫院。）

23 、Therefore, newer immunosuppressive agents such as mycophenolate mofetil and sirolimus (Rapa) have raised the possibility of withdrawing or avoiding CNIs altogether.───因此，新的免疫抑制劑如：麥考酚酸嗎乙酯和西羅莫司（雷帕霉素）的使用使CNI撤退或避免其使用的可行性上升。

24 、In addition, there are several practices that may reduce the risk of recurrence, i.e. use of rapamycin, which is an immunosuppressive agent with an anti-growth effect.───另外還可以通過(guò)幾種途徑來(lái)減少復發(fā)機會(huì )，如應用具有抗生長(cháng)作用的免疫抑制劑雷帕霉素等。

25 、Tamua K,Shibata Y,Matauda Y,et al.Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients[J].Cancer Res,1981,41 (10) :3244.───劉明佳,吳軍,包平,等.癌癥病人血清中免疫抑制酸性蛋白的測定[J].上海免疫學(xué)雜志,1996,16(4):216.

26 、Immunosuppressive drug FK506───免疫抑制劑FK506

27 、Experimental Study on the Immunosuppressive Activity of JHL Herbs───中藥復方JHL免疫抑制作用的實(shí)驗研究

28 、Methods:An immunosuppressive animal model was established by cyclophosphamide(CY).The T lymphocyte subsets were determined by flow cytometry(FCAS methods).───方法:環(huán)**酰胺腹腔注射建立小鼠免疫功能低下模型,應用流式細胞儀對小鼠T細胞亞群進(jìn)行檢測。

29 、Clinical Study of ALG/ATG as a Main Regimen of Immunosuppressive Therapy in Treatment of Severe Aplastic Anemia───ALG/ATG為主的免疫抑制劑治療重型再生障礙性貧血的臨床研究

30 、METHODS: To choose a scheme of the lowest cost to evaluate the maintenance effect of immunosuppressive.───方法:采用藥物經(jīng)濟學(xué)決策樹(shù)模型分析方法,選擇期望成本最小治療方案來(lái)評價(jià)免疫抑制維持的效果。

31 、Dixit V,Darvasi R,Arthur M,et al.Restoration of liver-function in Gunn rats without immunosuppress using transplanted microencapsulated hepatocyte[J].Hepatology,1990,12 (6),1342-1349.───宋繼昌李濤.用微囊肝細胞治療大鼠急性肝功能衰竭[J].中國生物醫學(xué)工程學(xué)報,:.

32 、Clinical Analysis of 15 Cases of Herpes Zoster Complicated in SLE Patients Treated with Immunosuppressive Therapy───免疫抑制治療系統性**時(shí)并發(fā)帶狀皰疹15例臨床分析

33 、Calcineurin inhibitors (cyclosporine or tacrolimus) comprised the immunosuppressive therapy in 49 pregnancies (94.2%).───49次妊娠（94.2%）是在采用包含鈣調神經(jīng)抑制劑（環(huán)孢素或他克莫司）的免疫抑制方案。

34 、Ten percent of the time, the immunosuppressants just aren't enough.─── 有10%的幾率 使用免疫抑制劑也無(wú)力回天

35 、This is treated by administering cyclosporine and other immunosuppressive agents.───可通過(guò)給予環(huán)胞霉素和其它免疫抑制劑治療。

36 、Keywords hepatitis B;immunosuppressive acidic protein（IAP）;prognosis;───乙型肝炎;免疫抑制酸性蛋白;預后;

37 、normal immunosuppressive protein───正常免疫抑制蛋白

38 、immunosuppressive acidic substance───免疫抑制的酸性物質(zhì)

39 、First, a uterus is ?transplanted from a donor, and the patient is ?put on immunosuppressants.─── 第一步 把捐獻者的子宮移植到受害者身上 并給他服用免疫抑制劑

40 、Methotrexate (MTX) was considered individually and, as the most widely prescribed immunosuppressive agent, used as the reference group for other therapies.───最常使用的免疫抑制劑MTX作為對照組被單獨評估。

41 、Immunopharmacology studies influence of drugs to immunity function of bodies.It includes immunomodulator and immunosuppressive drugs.───免疫藥理學(xué)研究藥物對機體免疫系統功能的影響，包括免疫調節劑和免疫抑制劑。

42 、The causes of vaccine failure were discuss ed,which includes the persistence of maternal antibodies,quality of vaccine,the immunosuppressive effect of parvovirus and variation of CDV.───分析免疫失敗的原因,主要是母源抗體干擾、疫苗質(zhì)量差、其它病毒的免疫抑制以及CDV流行株可能發(fā)生了變異等因素的影響。

43 、The immunosuppressive activity of ALbG is 4.16 tims more than that of ALG.───ALbG的花環(huán)抑制活性比ALG強4.16倍。

44 、Stress is itself immunosuppressive and will increase the effects of ISVs.───應激本身就會(huì )抑制免疫功能，所以會(huì )加重ISV導致的病情。

45 、Methods:Mogrosides was administered to normal or CTX-induced immunosuppressive mice, and their macrophage function and T lymphocyte proliferation were detected.───方法:用羅漢果甜甙給正常和環(huán)**酰胺(CTX)抑制小鼠灌胃,檢測小鼠巨噬細胞吞噬功能和T細胞的增殖作用。

46 、Study of the effects of immunosuppressive agents on human islet cells in vitro───免疫抑制劑對成人胰島細胞的毒性作用的體外觀(guān)察

47 、immunosuppressive acid protein───免疫抑制酸性蛋白

48 、The feeding of low antigen doses leads to induction of regulatory cell secretion of immunosuppressive cytokines,whereas higher doses favor clonal deletion and anergy.───低劑量口服抗原主要通過(guò)調節性T細胞分泌抑制性細胞因子介導免疫抑制,高劑量口服抗原主要引起T細胞清除或T細胞失能。

49 、Abstract Purpose : to evaluate the changes af the serum levels of immunosuppressive acidic protein ( IAP) in patients with large bowel carcinoma (LBC) and their familial members ( FM) .───摘要 目的:評估大腸癌(LBC) 患者及其家族成員(FM) 血清免疫抑制酸性蛋白( IAP) 水平的變化。

50 、Research Progression of Toxicity of Immunosuppressive Agent in Treatment of Rheumatism───免疫抑制藥物治療風(fēng)濕病不良反應研究進(jìn)展

51 、Effect of Multiple Immunosuppressive Viral Infections on Pathogenesis and Epidemiology in Chicken Flocks───免疫抑制**毒多重感染在雞群疫病發(fā)生和流行中的作用

52 、Biotics have a mutated p36 immunosuppressant gene that renders them immune to all poisons.─── 生化人有一個(gè)變異p36免疫抑制基因 能讓他們百毒不侵

53 、He probably used it as an immunosuppressant.─── 他可能是用它來(lái)做免疫抑制劑的

54 、We reported a 37-year-old man, a Myanmar immigrant, with established pulmonary histoplasmosis.No known risk factors, such as AIDS or immunosuppressive therapy, were identified.───我們在此報告一個(gè)最后被診斷為肺組織漿菌病的37歲男性，該病人除了是緬甸移民之外，并沒(méi)有其他已知的危險因子，例如AIDS或免疫抑制劑的使用等。

55 、Methods Different dosages of Immunologic Syrup were orally given to normal and immunosuppressive mice, respectively.The mouse NK cells activity were detected at the 11th day after the treatment.───方法用不同劑量免疫口服液給正常小鼠和環(huán)**酰胺免疫抑制小鼠灌胃,于第11d分別檢測小鼠NK細胞的活性。

56 、Conventional immunosuppressive treatments include steroids that may induce insulin resistance and are responsible for many side effects.───常規的包括類(lèi)固醇激素的免疫抑制治療可能引起胰島素抵抗，且存在很多并發(fā)癥。

57 、When the immunological vasculitis was confirmed, Most patients should be treated with a combination of immunosuppressive medications.───對自身免疫性血管炎的治療首選聯(lián)合應用皮質(zhì)激素和環(huán)**酰胺。

58 、The modulation effects of the medicine on the immune function of the immunosuppressive mice were assayed by such tests as macrophage phagocyte rate.───本研究采用巨噬細胞吞噬試驗、脾指數測定、血清溶血素和淋巴細胞轉化試驗（MTT法），檢測了該藥對免疫功能低下小鼠免疫功能的調節作用。

59 、Methods Immunosuppress and ICMA were used to perform the activation and quality of CK-MB together.───方法采用免疫化學(xué)發(fā)光法和免疫抑制法同步檢測血清中CK-MB的質(zhì)量和活性。

60 、Dynamic observation on the biochemical index in the immunosuppressive mice experimentally infected with Taenia sagi-nata asiatica in Duyun City and Taenia saginata in Congjiang City.───摘要:目的觀(guān)察貴州省兩種牛帶絳蟲(chóng)感染小鼠生化指標動(dòng)態(tài)改變。

61 、Immunosuppressive therapy of multiple sclerosis───多發(fā)性硬化的免疫抑制治療

62 、"The patients with disease recurrence had these immunosuppressive molecules in their tumors," he said.───“疾病復發(fā)的患者腫瘤中有這些免疫抑制分子，”他說(shuō)。

63 、Immunosuppressive and immunomodulatory therapies have been shown to alter to some extent the long-term course of multiple sclerosis (MS).───多發(fā)性硬化的免疫抑制與免疫調節治療在一定程度上改變了多發(fā)性硬化的長(cháng)期病程。

64 、triple immunosuppressive therapy───三聯(lián)免疫抑制治療

65 、Intensive Immunosuppressive Therapy for Children with Severe Aplastic Anemia───強化免疫抑制治療兒童再生障礙性貧血療效分析

66 、To research the immunosuppressive function of Pellodendron, we used DTH mouse model induced by DNFB to study the effects of Pellodendron on levels of DTH and several cellular factors.───為進(jìn)一步探討黃柏免疫抑制作用 ,我們以二硝基氟苯 (DNFB)所致遲發(fā)型超敏反應 (DTH)小鼠模型觀(guān)察黃柏對小鼠DTH及其體內幾種重要細胞因子的影響。

67 、Study of Immunosuppressive Acidic Protein in Patients with Malignant Tumors in Oral and Maxillofacial Regions───口腔頜面部惡性腫瘤患者血清免疫抑制酸性蛋白的研究

68 、In this article, a girl with an especially severe form of autoimmune acute hepatitis was successfully treated with immunosuppressive medication.───摘要在此報告一個(gè)特別嚴重的自體免疫性急性肝炎的女孩，最后以免疫抑制劑治療成功；

69 、Immunosuppressive medications ( ciclosporin , plasmapheresis).───免疫抑制藥物（ 環(huán)孢素 ，血漿置換） 。

70 、Leflunomide and mycophenolate mofeli have similar immunosuppressive mechanism and good therapeutic ef-fects.───來(lái)氟米特、麥考酚酯的免疫抑制機制類(lèi)似，療效明確。

71 、Keywords Immunosuppressive agents;Lymphopenia;Mice;inbred strains;───關(guān)鍵詞免疫抑制劑;淋巴細胞減少;小鼠;近交系;

72 、Glucocorticoids have been used as anti-inflammatory and immunosuppressive agents for a long time in clinical application.But several questions on mechanisms of pharmacological actions remain.───摘要 糖皮質(zhì)激素作為抗炎藥物和免疫抑制劑在臨床應用已有較長(cháng)歷史，但在藥理作用機制方面尚有未解的問(wèn)題。

73 、RSJ can improve the immune function of rats and can decrease the immunosuppressive effect.───RSJ可提高小鼠的免疫功能 ,具有對抗免疫抑制的作用。

74 、This immunosuppressant will save your life and allow you to reach your full potential.─── 這種抑制劑可以挽救你的性命 還能讓你發(fā)揮出全部潛能

75 、Different usages of immunosuppressive agents for treating thyroid-associated eye disease───免疫抑制劑不同用法治療甲狀腺相關(guān)性眼病對照研究

76 、Thomas's lumbar puncture confirmed he has viral meningitis, most likely because he's immunosuppressed.─── 托馬斯的脊椎穿刺證實(shí)了 他得了病毒性腦膜炎 很可能是由他的免疫功能不全導致

77 、Digital gangrene progressed with right index finger amputated in spite of cessation of smoking, parenteral prostaglandin, immunosuppressive, and anticoagulant therapy.───最初的表現為手指壞疽，盡管在停止抽煙、用前列腺素、疫抑制劑及抗凝血劑的情況下，仍然持續惡化，最后右手食指截肢。

78 、A cholinesterase inhibitor (ChEI) and immunosuppressive therapy were applied for treatment.───一種膽堿酯酶抑制劑和免疫抑制療法用于治療。

79 、The patients were conditioned with decreased dosage of immunosuppressive agents of CTX (60?mg/kg) and ALG (120?mg/kg).───CTX總用量為 6 0mg/kg ; ALG為 12 0mg/kg。

80 、The immunosuppressive regimen consisted of tacrolimus, prednisolone, mycophenolate mofetil (or cyclophosphamide), and prostaglandin E1 in all patients.───免疫抑制方案包括他克莫司、強的松、霉酚酸酯（或環(huán)**酰胺）和前列腺素E1。

81 、Method:We determined and compared the several index of humoral nonspecific and specific immunity in the normal mice and immunosuppressive mice.───方法：檢測了正常及免疫受抑小鼠機體非特異性和特異性免疫功能的幾項指標，并進(jìn)行比較分析。

82 、Poisoning by antineoplastic and immunosuppressive drug───抗腫瘤和免疫抑制藥中毒

83 、immunosuppressive acidic protein(IAP)───免疫抑制酸性蛋白[惡性腫瘤組織及血清的相關(guān)物質(zhì), 對腫瘤宿主免疫系統具有顯著(zhù)的抑制作用]

84 、Clinical studies on treatment for lupus nephritis with different lash therapy of immunosuppressive agent───免疫抑制劑不同沖擊療法治療狼瘡性腎炎的臨床研究

85 、Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer.───免疫抑制蛋白B7同系物1(B7-H1)，亦稱(chēng)程序性死亡配體1(PD-L1)在包括癌癥等許多病變中表達增高。

86 、The next step would be immunosuppressive therapy, which could slow down viral replication by limiting the T cell activation and prevent the CD4+ T cells from committing suicide.───接下來(lái)，就是采用免疫抑制療法，藉由限制T細胞的活化來(lái)減少病毒的復制，并阻止CD4+T細胞的凋亡。

87 、immunosuppressive drug therapy───免疫抑制藥物療法

88 、The use of new immunosuppressive drugs has further improved clinical results.───使用了新型的免疫抑制藥物是取得好的臨床效果的保證。

89 、antineoplastic and immunosuppressive agents───抗腫瘤藥和免疫抑制藥

90 、quadraple immunosuppressive therapy───四聯(lián)免疫抑制治療

immunity與immunization的區別？

意思上的區別：

immunity 是免除免疫力

immunization 是免疫

何曉順的近年論著(zhù)

1. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X（通訊作者）. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012 Jan;18(1):62-9. doi: 10.1002/lt.22441.

2. Zhou J, Ju W, Wang D, Wu L, Zhu X, Guo Z, He X（通訊作者）. Down-regulation of microRNA-26a promotes mouse hepatocyte proliferation during liver regeneration. PLoS One. 2012;7(4):e33577. Epub 2012 Apr 4.

3. Ju WQ, Guo ZY, Liang WH, Wu LW, Tai Q, Hu AB, Han M, Zhu XF, He X（通訊作者）. Sirolimus conversion in liver transplant recipients with calcineurin inhibitor-induced complications: efficacy and safety. Exp Clin Transplant. 2012 Apr;10(2):132-5.

4. Ling X, Xiong J, Liang W, Schroder PM, Wu L, Ju W, Kong Y, Shang Y, Guo Z, He X（通訊作者）.Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation. 2012 Apr 15;93(7):737-43.

5. Wu LW, Guo ZY, Tai Q, Ju WQ, Wang DP, Hu AB, Zhu XF, He XS（通訊作者）.Steroid elimination within 24 hours after orthotopic liver transplantation: effectiveness and tolerability. Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):137-42.

6. Chen M, Guo Z, Ju W, Ryffel B, He X（通訊作者）, Zheng SG. The development and function of follicular helper T cells in immune responses. Cell Mol Immunol. 2012 Jun 4. doi: 10.1038/cmi.2012.18. [Epub ahead of print]

7. Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X（通訊作者）. Living donor versus deceased donor liver transplantation for hepatocellular carcinoma: A meta-analysis. Liver Transpl. 2012 Jun 9. doi: 10.1002/lt.23490. [Epub ahead of print]

8. Shang Y, Ju W, Kong Y, Schroder PM, Liang W, Ling X, Guo Z, He X（通訊作者）. Performance of polymerase chain reaction techniques detecting perforin in the diagnosis of acute renal rejection: a meta-analysis. PLoS One. 2012;7(6):e39610. Epub 2012 Jun 29.

9. Hu A, Liang W, Zheng Z, Guo Z, He X（通訊作者）. Living Donor versus Deceased Donor Liver Transplantation for Patients with Hepatitis C Virus-Related Diseases: J.Hepatol.2012 Dec;57(6):1228-43.

10. Wu L, Hu A, Tam N, Zhang J, Lin M, Guo Z,He X（通訊作者）. Salvage liver transplantation for patients with recurrent hepatocellular carcinoma after curative resection. PLoS One. 2012;7(7):e41820. Epub 2012 Jul 26.

11. Ju WQ, Guo ZY, Ling X, He XS（通訊作者）, Wu LW, Tai Q, Hu AB, Han M, Zhu XF.Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients.Exp Clin Transplant. 2012 Jun;10(3):258-62.

12. Ju W, Chen M, Guo Z, Wang D, Zhu X, Huang J, He X（通訊作者）. Allografts Positive for Hepatitis B Surface Antigen in Liver Transplant for Disease Related to Hepatitis B Virus.Exp Clin Transplant. 2012 Nov 20. doi: 10.6002/ect.2012.0095. [Epub ahead of print]

13. Chen Y, Tai Q, Hong S, Kong Y, Shang Y, Liang W, Guo Z, He X（通訊作者）.Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis.Transplantation. 2012 Nov 15;94(9):911-8.

14. Kong Y, Wang X, Shang Y, Schroder PM, Liang W, Ling X, Guo Z, He X（通訊作者）. Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis. PLoS One. 2012;7(12):e52158.

15. Hu AB, Wu LW, Tai Q, He XS（通訊作者）, Zhu XF. Safety and efficacy of four steroid-minimization protocols in liver transplant recipients: 3-year follow-up in a single center. J Dig Dis. 2013; 14; 38–44.

16. Hu A, Li Q, Shi H, Tai Q, Wu L, Xiong J, Fu B, He X（通訊作者）. Donor-derived bone marrow transfusion produces mixed chimerism and promotes a Th2 shift in Th1/Th2 balance in rat heterotopic small bowel transplantation. Dig Liver Dis. 2012 Dec; 44(12): 988-94.

17. Wu L, Zhang J, Guo Z, Tai Q, He X（通訊作者）, Ju W, Wang D, Zhu X. Diagnosis and treatment of acute appendicitis after orthotopic liver transplant in adults. Exp Clin Transplant. 2011 Apr;9(2):113-7.

18. Wu L, Zhang J, Guo Z, Tai Q, He X（通訊作者）, Ju W, Wang D, Zhu X, Ma Y, Wang G, Hu A. Hepatic artery thrombosis after orthotopic liver transplant: a review of the same institute 5 years later. Exp Clin Transplant. 2011 Jun;9(3):191-6.

19. Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z, He X（通訊作者）. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One. 2011;6(9):e24387. Epub 2011 Sep 9

20. Wang S, He X（通訊作者）, Li Z, Peng Z, Tam NL, et al. (2010) Characterization of the middle hepatic artery and its relevance to living donor liver transplantation. Liver Transpl 16: 736-741.

21. Guo Z, Wang G, Miyahara Y, Khattar M, Linkes SP, Changxi Wang, Jiahong Xia, Yiqing Pan, Wenhao Chen, Xiaoshun He（通訊作者）, Stanislaw M. Stepkowski. (2010) IL-7, but not thymic stromal lymphopoietin (TSLP), during priming enhances the generation of memory CD4+ T cells. Immunol Lett 128: 116-123.

22. Guo Z, He X（通訊作者）, Wu L, Ju W, Hu A, et al. (2010) Model for end-stage liver disease versus the Child-Pugh score in predicting the post-transplant 3-month and 1-year mortality in a cohort of Chinese recipients. Surgery Today 40: 38-45.

23. Fu BM, He XS（通訊作者）, Yu S, Hu AB, Zhang J, et al. (2010) A tolerogenic semimature dendritic cells induce effector T-cell hyporesponsiveness by activation of antigen-specific CD4+CD25+T regulatory cells that promotes skin allograft survival in mice. Cell Immunol 261: 69-76.

24. 胡安斌，何曉順（通訊作者），邰強等, 索拉非尼在預防和治療肝癌肝移植術(shù)后腫瘤復發(fā)中的療效評價(jià). 中華醫學(xué)雜志, 2012. 92(18): 1264-1267.

25. 周健, 鞠衛強，何曉順（通訊作者）等, 肝移植術(shù)后早期并發(fā)消化道漏的臨床特點(diǎn)和診治分析. 中華外科雜志, 2012. 50(3): 222-225.

26. 鞠衛強, 吳志鵬，何曉順（通訊作者）等, 缺血預處理減輕大鼠供肝冷保存損傷的作用及其機制. 中華器官移植雜志, 2012. 33(3): 156-159.

27. 何曉順（通訊作者）, 巫林偉，朱曉峰等, 胰腎聯(lián)合移植治療肝移植后糖尿病合并腎功能衰竭二例. 中華器官移植雜志, 2012. 33(2): 94-96.

28. 鞠衛強, 何曉順（通訊作者），王東平等, 乙型肝炎表面抗原**供肝在肝移植中的應用. 中華肝臟病雜志, 2012. 20(1): 14-16.

29. 鞠衛強, 何曉順（通訊作者），郭志勇等, 成人肝移植術(shù)后早期肝動(dòng)脈血栓形成的診斷與治療. 中華肝膽外科雜志, 2012. 18(1): 19-22.

30. 何曉順（通訊作者）, 鞠衛強，朱曉峰等, 上腹部多器官移植治療終末期肝病合并2型糖尿病. 中華器官移植雜志, 2012. 33(9): 531-535.

31. 鞠衛強, 周健，何曉順（通訊作者）等, 肝胰十二指腸器官簇移植圍手術(shù)期營(yíng)養支持療法探討. 中華臨床營(yíng)養雜志, 2012. 20(2): 74-77.

32. 周健, 鞠衛強，何曉順（通訊作者）等, 肝移植后近期并發(fā)胃腸道漏營(yíng)養支持經(jīng)驗. 中華移植雜志（電子版）, 2012. 06(1): 25-28.

33. 鞠衛強, 何曉順（通訊作者），郭志勇等, 肝胰十二指腸器官簇移植術(shù)后的免疫抑制治療. 中華普通外科學(xué)文獻（電子版）, 2012. 06(1): 17-21.

34. 周健, 鞠衛強，何曉順（通訊作者）等, 肝移植治療肝臟上皮樣血管內皮瘤2例報告并文獻復習. 中華普通外科學(xué)文獻(電子版), 2012. 6(04): 28-31.

35. 巫林偉, 何曉順（通訊作者），胡安等, 胰腎聯(lián)合移植術(shù)后的免疫抑制治療. 中華普通外科學(xué)文獻（電子版）, 2010. 04(4): 360-363.

36. 巫林偉, 何曉順（通訊作者），邰強等, 原位肝移植術(shù)后并發(fā)粒細胞缺乏7例臨床分析. 中華移植雜志（電子版）, 2010. 04(4): 285-288.

37. 邰強, 何曉順（通訊作者），胡安斌等, 肝移植術(shù)后大腸埃希菌血行感染耐藥及危險因素分析. 中華醫學(xué)雜志, 2011. 91(42): 2977-2980.

38. 鞠衛強, 何曉順（通訊作者），邰強等, 肝移植中應用巴利昔單抗誘導治療的免疫抑制方案的療效. 中華器官移植雜志, 2011. 32(9): 542-544.

39. 邰強, 何曉順（通訊作者），巫林偉等, 肝移植后革蘭陰性菌血行感染的流行病學(xué)和耐藥性回顧性分析. 中華器官移植雜志, 2011. 32(9): 549-552.

40. 鞠衛強, 周健，何曉順（通訊作者）等, 供受者ABO血型不符的成人肝臟移植療效評價(jià). 中華醫學(xué)雜志, 2011. 91(36): 2558-2560.

41. 何曉順（通訊作者）, 調節性T細胞誘導移植免疫耐受研究現狀與展望. 中華實(shí)驗外科雜志, 2010. 27(3): 277-278.

42. 巫林偉, 何曉順（通訊作者），邰強等, 激素最小化免疫抑制方案在肝移植術(shù)后的應用. 中華外科雜志, 2010. 48(7): 492-495.

43. 鞠衛強, 吳志鵬，何曉順（通訊作者）等, 缺血預處理對大鼠冷保存供肝線(xiàn)粒體膽固醇含量和細胞色素C釋放的影響. 中華肝臟病雜志, 2011. 19(6): 473-474.

44. 何曉順（通訊作者）, 巫林偉，郭志勇等, 挽救性肝移植治療肝癌切除術(shù)后腫瘤復發(fā). 中華器官移植雜志, 2011. 32(6): 343-346.

45. 何曉順（通訊作者）, 巫林偉，朱曉峰等, 腹部器官簇移植治療終末期肝病合并胰島素依賴(lài)的2型糖尿病五例. 中華器官移植雜志, 2011. 32(5): 260-263.

46. 朱曉峰, 何曉順（通訊作者），鄧斐文等, 胰腺聯(lián)合腎臟或肝臟移植后長(cháng)期存活受者胰島功能及相關(guān)代謝的比較研究. 中華器官移植雜志, 2011. 32(5): 264-267.

47. 何曉順（通訊作者）, 鞠衛強，黃潔夫, 器官移植中心器官聯(lián)合移植的歷史、現狀及展望. 中華器官移植雜志, 2011. 32(5): 257-259.

48. 鞠衛強, 吳志鵬，何曉順（通訊作者）等, 缺血預處理對大鼠冷保存供肝細胞HMG-CoA還原酶活力的影響. 中華實(shí)驗外科雜志, 2011. 28(8): 1315-1317.

49. 周健, 鞠衛強，何曉順（通訊作者）等, 腎移植術(shù)后肝移植四例. 中華器官移植雜志, 2011. 32(5): 312-313.

50. 邰強, 何曉順（通訊作者），巫林偉等, 胰腎聯(lián)合移植改善糖尿病繼發(fā)病變的初步研究. 中華普通外科學(xué)文獻（電子版）, 2010. 04(5): 434-437.

51. 周健, 鞠衛強，何曉順（通訊作者）等, 無(wú)心跳供體小腸獲取一例報告. 中華普通外科雜志, 2011. 26(4): 345-346.

52. 周健, 鞠衛強，何曉順（通訊作者）等, Campath-1H誘導在小腸移植免疫抑制中的作用. 中華胃腸外科雜志, 2011. 14(3): 199-201.

53. 鞠衛強, 何曉順（通訊作者），邰強等, 內鏡下逆行胰膽管造影術(shù)在肝移植術(shù)后膽道并發(fā)癥中的應用. 中華臨床醫師雜志（電子版）, 2011. 05(6): 1597-1600.

54. 周健, 鞠衛強，何曉順（通訊作者）等, 全小腸移植的營(yíng)養支持一例. 中華臨床營(yíng)養雜志, 2011. 19(6): 412.

55. 何曉順（通訊作者），郭志勇, 規范管理,推進(jìn)我國人體器官捐獻工作有序開(kāi)展. 中華移植雜志（電子版）, 2010. 4(1): 7-9.

56. 邰強, 何曉順（通訊作者），廖康等, 肝移植術(shù)后血行感染中產(chǎn)超廣譜β內酰胺酶大腸埃希菌、肺炎克雷伯菌流行病學(xué)、細菌學(xué)及臨床回顧性分析. 中華普通外科學(xué)文獻(電子版), 2011. 05(5): 421-424.

57. 談雅莉, 巫林偉，何曉順（通訊作者）等, 器官移植法規對我國內地肝移植的影響. 中華移植雜志（電子版）, 2011. 05(3): 57-59.

58. 巫林偉, 何曉順（通訊作者），郭志勇等, 肝移植術(shù)后激素24小時(shí)撤離的安全性. 中華普通外科學(xué)文獻（電子版）, 2011. 05(2): 133-136.

59. 周健, 鞠衛強，何曉順（通訊作者）等, 肝移植術(shù)后二次腹腔大出血：抗凝過(guò)度? 中華普通外科學(xué)文獻（電子版）, 2011. 05(1): 48-49.

60. 周健，何曉順（通訊作者）, 小肝綜合征的研究進(jìn)展. 中華普通外科學(xué)文獻(電子版), 2011. 5(01): 54-58.

61. 王東平, 唐決，何曉順（通訊作者）等, 上腹部器官簇移植治療多器官病變的臨床分析. 中華外科雜志, 2010. 48(23): 1800-1804.

62. 鞠衛強, 何曉順（通訊作者），王東平等, 西羅莫司在肝移植術(shù)后鈣調素類(lèi)抑制劑相關(guān)腎損病人中的應用. 中華肝膽外科雜志, 2010. 16(2): 112-114.

63. 巫林偉, 何曉順（通訊作者），鞠衛強等, 肝移植術(shù)后肝動(dòng)脈血栓形成的預防. 中華普通外科雜志, 2010. 25(2): 95-97.

64. 邰強, 何曉順（通訊作者），楊建安等, 肝移植術(shù)后膽道并發(fā)癥的診斷與治療. 中華普通外科雜志, 2010. 25(12): 969-972.

65. 鞠衛強, 何曉順（通訊作者），吳志鵬等, 不同冷保存時(shí)間的熱缺血供肝在肝移植中的療效. 中華消化外科雜志, 2010. 9(1): 41-43.

66. 何曉順（通訊作者）, 鞠衛強，郭志勇等, 國內首例小兒供肝應用于成人肝移植報告. 中華外科雜志, 2010. 48(20): 1597-1598.

67. 韓明, 何曉順（通訊作者），馬毅等, 原位肝移植治療多囊肝病的臨床分析. 中華普通外科雜志, 2010. 25(2): 102-105.

68. 邰強, 何曉順（通訊作者），楊建安等, 大鼠肝移植供肝熱缺血時(shí)間與膽道損傷的關(guān)系. 中華實(shí)驗外科雜志, 2010. 27(10): 1457-1459.

69. 馬毅, 何曉順（通訊作者），朱曉峰，等胰腎聯(lián)合移植的外科技術(shù)探討. 中華普通外科雜志, 2010. 25(4): 265-268.